Literature DB >> 31147820

Autoinflammatory Pathogenesis and Targeted Therapy for Adult-Onset Still's Disease.

Sheng Li1, Siting Zheng1, Shunli Tang1, Yunlei Pan1, Shan Zhang1, Hong Fang2, Jianjun Qiao3.   

Abstract

Adult-onset Still's disease (AOSD) is a rare multisystem autoinflammatory disorder of unknown etiology. AOSD is generally characterized by high spiking fever, arthralgia or arthritis, skin rash, leukocytosis, and hyperferritinemia. Traditionally, AOSD has been treated with non-steroidal anti-inflammatory drugs, corticosteroids, and immunosuppressants. An increasing number of studies have shown that proinflammatory cytokines, such as interleukin-1β, -18, -6, and tumor necrosis factor-α, play key roles in AOSD and may serve as therapeutic targets. In the current review, we provided insights into the roles of these cytokines in the pathogenesis of AOSD and also provided a commentary on the clinical studies of biologic therapy against AOSD.

Entities:  

Keywords:  Adult-onset Still’s disease; Autoinflammatory disease; Cytokines; Pathophysiology; Targeted therapy

Mesh:

Substances:

Year:  2020        PMID: 31147820     DOI: 10.1007/s12016-019-08747-8

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   10.817


  86 in total

1.  Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial.

Authors:  George D Kalliolias; Panagiotis E Georgiou; Ioannis A Antonopoulos; Andrew P Andonopoulos; Stamatis-Nick C Liossis
Journal:  Ann Rheum Dis       Date:  2007-06       Impact factor: 19.103

2.  Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease.

Authors:  T Fujii; T Nojima; H Yasuoka; S Satoh; K Nakamura; M Kuwana; A Suwa; M Hirakata; T Mimori
Journal:  Rheumatology (Oxford)       Date:  2001-12       Impact factor: 7.580

Review 3.  Proteolytic Processing of Interleukin-1 Family Cytokines: Variations on a Common Theme.

Authors:  Inna S Afonina; Christina Müller; Seamus J Martin; Rudi Beyaert
Journal:  Immunity       Date:  2015-06-16       Impact factor: 31.745

4.  HLA-Bw35 and prognosis in adult Still's disease.

Authors:  R Terkeltaub; J M Esdaile; F Décary; M Harth; J Lister; N Lapointe
Journal:  Arthritis Rheum       Date:  1981-12

5.  Nationwide epidemiological survey of 169 patients with adult Still's disease in Japan.

Authors:  Yu Funakubo Asanuma; Toshihide Mimura; Hiroto Tsuboi; Hisashi Noma; Fumihiko Miyoshi; Kazuhiko Yamamoto; Takayuki Sumida
Journal:  Mod Rheumatol       Date:  2014-11-10       Impact factor: 3.023

6.  The use of Canakinumab, a novel IL-1β long-acting inhibitor, in refractory adult-onset Still's disease.

Authors:  Apostolos Kontzias; Petros Efthimiou
Journal:  Semin Arthritis Rheum       Date:  2012-04-17       Impact factor: 5.532

7.  A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years.

Authors:  Hideko Nakahara; Toru Mima; Naoko Yoshio-Hoshino; Masato Matsushita; Jun Hashimoto; Norihiro Nishimoto
Journal:  Mod Rheumatol       Date:  2008-09-02       Impact factor: 3.023

8.  Differential requirement for the activation of the inflammasome for processing and release of IL-1beta in monocytes and macrophages.

Authors:  Mihai G Netea; Claudia A Nold-Petry; Marcel F Nold; Leo A B Joosten; Bastian Opitz; Jonathan H M van der Meer; Frank L van de Veerdonk; Gerben Ferwerda; Bas Heinhuis; Isabel Devesa; C Joel Funk; Robert J Mason; Bart Jan Kullberg; Anna Rubartelli; Jos W M van der Meer; Charles A Dinarello
Journal:  Blood       Date:  2008-12-22       Impact factor: 22.113

9.  Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.

Authors:  Linda Rossi-Semerano; Bruno Fautrel; Daniel Wendling; Eric Hachulla; Caroline Galeotti; Luca Semerano; Isabelle Touitou; Isabelle Koné-Paut
Journal:  Orphanet J Rare Dis       Date:  2015-02-15       Impact factor: 4.123

10.  Highly Expression of CD11b and CD32 on Peripheral Blood Mononuclear Cells from Patients with Adult-Onset Still's Disease.

Authors:  Hyoun-Ah Kim; Bunsoon Choi; Chang-Hee Suh; Mi Hwa Han; Ju-Yang Jung; Hasan M Sayeed; Ye Won Kim; Seonghyang Sohn
Journal:  Int J Mol Sci       Date:  2017-01-19       Impact factor: 5.923

View more
  12 in total

1.  Bibliometrics and Visual Analysis of Adult-onset Still Disease (1976-2020).

Authors:  Bowen Xu; Jian Wang; Xiaoying Meng; Binghao Bao
Journal:  Front Public Health       Date:  2022-06-15

2.  Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease.

Authors:  Antonio Vitale; Virginia Berlengiero; Jurgen Sota; Luisa Ciarcia; Nicola Ricco; Sara Barneschi; Mariam Mourabi; Giuseppe Lopalco; Chiara Marzo; Francesca Bellisai; Florenzo Iannone; Bruno Frediani; Luca Cantarini
Journal:  Mediators Inflamm       Date:  2020-10-15       Impact factor: 4.711

Review 3.  Neutrophils in the Pathogenesis of Rheumatic Diseases: Fueling the Fire.

Authors:  Yudong Liu; Mariana J Kaplan
Journal:  Clin Rev Allergy Immunol       Date:  2020-11-05       Impact factor: 8.667

Review 4.  Autoinflammatory and autoimmune conditions at the crossroad of COVID-19.

Authors:  Yhojan Rodríguez; Lucia Novelli; Manuel Rojas; Maria De Santis; Yeny Acosta-Ampudia; Diana M Monsalve; Carolina Ramírez-Santana; Antonio Costanzo; William M Ridgway; Aftab A Ansari; M Eric Gershwin; Carlo Selmi; Juan-Manuel Anaya
Journal:  J Autoimmun       Date:  2020-06-16       Impact factor: 7.094

5.  Parenchymal lung disease in adult onset Still's disease: an emergent marker of disease severity-characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients.

Authors:  Piero Ruscitti; Onorina Berardicurti; Daniela Iacono; Ilenia Pantano; Vasiliki Liakouli; Francesco Caso; Giacomo Emmi; Rosa Daniela Grembiale; Francesco Paolo Cantatore; Fabiola Atzeni; Federico Perosa; Raffaele Scarpa; Giuliana Guggino; Francesco Ciccia; Antonio Barile; Paola Cipriani; Roberto Giacomelli
Journal:  Arthritis Res Ther       Date:  2020-06-22       Impact factor: 5.156

Review 6.  The innate immune perspective of autoimmune and autoinflammatory conditions.

Authors:  Shirly Frizinsky; Soad Haj-Yahia; Diti Machnes Maayan; Yulia Lifshitz; Ramit Maoz-Segal; Irean Offengenden; Mona Kidon; Nancy Agmon-Levin
Journal:  Rheumatology (Oxford)       Date:  2019-11-01       Impact factor: 7.580

7.  Adult-Onset Still's Disease With Severe Hyperferritinemia and the Asian Salmon-Pink Rash: A Case Report.

Authors:  Toshiki Fukunaga; Ryuichi Ohta; Fumiko Yamane; Chiaki Sano
Journal:  Cureus       Date:  2022-06-23

Review 8.  An Update on the Pathogenic Role of Macrophages in Adult-Onset Still's Disease and Its Implication in Clinical Manifestations and Novel Therapeutics.

Authors:  Po-Ku Chen; Der-Yuan Chen
Journal:  J Immunol Res       Date:  2021-06-20       Impact factor: 4.818

9.  Elevated serum levels of checkpoint molecules in patients with adult Still's disease.

Authors:  Yuya Fujita; Tomoyuki Asano; Haruki Matsumoto; Naoki Matsuoka; Jumpei Temmoku; Shuzo Sato; Makiko Yashiro Furuya; Eiji Suzuki; Hiroshi Watanabe; Tomohiro Koga; Atsushi Kawakami; Kiyoshi Migita
Journal:  Arthritis Res Ther       Date:  2020-07-22       Impact factor: 5.156

10.  Case Report: Adult Still's Disease in an Alemtuzumab-Treated Multiple Sclerosis Patient.

Authors:  Julia Krämer; Tanja Krömer-Olbrisch; Heinz-Jürgen Lakomek; Peter D Schellinger; Dirk Foell; Sven G Meuth; Vera Straeten
Journal:  Front Immunol       Date:  2020-08-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.